Future of MDx After Covid-19 Crisis in APAC

The future of molecular diagnostics post-covid in APAC

Molecular-based testing has become fundamental to many countries’ efforts to return to normalcy in the covid-19 pandemic. The growth of the molecular diagnostics (MDx) market is most apparent in the Asia-Pacific (APAC) region. Economist Intelligence Clearstate anticipates that MDx related investments and increasing MDx capabilities indicate strong growth potential for the region’s overall molecular testing market over the next few years.This report examines how the covid-19 pandemic has shifted the dynamics of molecular testing in APAC, as well as the future of the region’s MDx market. As molecular testing capabilities advance, will covid-19 related investments benefit other test areas?

Download free report

Clearstate newsletter

The latest trends and insights into the IVD and Surgical sectors, from our specialists and analysts, delivered directly to your inbox. Sign up to Clearstate's newsletter today.